GlassScriptPhysician profile
Ayesha Munir
NPI 1386174563
$2,949.61
in general payments reported to CMS, 2019-2025
38 companies · $1,818 in 2025
The $1,818 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $326 · 2024: $806 · 2025: $1,818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,197 · Long Term Medical Supply Or Device Loan: $499 · Education: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,197.14 |
| Long Term Medical Supply Or Device Loan | $498.50 |
| Education | $253.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $615.31 | 2024-2025 | |
| Janssen Biotech, INC. | $294.02 | 2023-2025 | Erleada, Balversa, Akeega |
| Incyte Corporation | $197.78 | 2023-2024 | Monjuvi |
| Daiichi Sankyo INC. | $180.70 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Regeneron Healthcare Solutions, INC. | $163.40 | 2023-2024 | Libtayo |
| Eisai INC. | $123.11 | 2023-2024 | |
| Tersera Therapeutics LLC | $116.35 | 2024-2025 | Quzyttir, Xermelo, Zoladex |
| Emd Serono, INC. | $92.79 | 2024-2025 | |
| Abbvie INC. | $86.79 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $81.67 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $77.57 | 2025 | Reblozyl |
| Pfizer INC. | $75.64 | 2025 | |
| Gilead Sciences, INC. | $73.75 | 2023-2025 | Trodelvy |
| Immunocore Limited | $66.27 | 2025 | Kimmtrak |
| Genmab U.S., INC. | $62.27 | 2024-2025 | Epkinly |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayesha Munir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.